Treatment Options for Myelodysplastic Syndromes

National Comprehensive Cancer Network Practice Guidelines in Oncology V1.2004. Myelodysplastic syndromes. 10/31/2003 National Comprehensive Cancer Network. Available at: http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf. Accessed September 7, 2004.

Gordon M.S. Advances in supportive care of myelodysplastic syndromes. Semin Hematol. 1999; 36(4 suppl 6): 21–24.

Tricot G.J. , Lauer R.C. , Appelbaum F.R. Management of the myelodysplastic syndromes. Semin Oncol. 1987; 14: 444–453.

Blinder V.S. , Roboz G.J. Hematopoietic growth factors in myelodysplastic syndromes. Curr Hematol Rep. 2003; 2: 453–458.

Hellstrom-Lindberg E. Approach to anemia associated with myelodysplastic syndromes. Curr Hematol Rep. 2003; 2: 122–129.

Hellstrom-Lindberg E. , Negrin R. , Stein R. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol. 1997; 99: 344–351.

Hellstrom-Lindberg E. , Gulbrandsen N. , Lindberg G. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony stimulating factor: significant effects on quality of life. Br J Haematol. 2003; 120: 1037–1046.

Kurzrock R. , Cortes J. , Thomas D.A. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol. 2001; 19: 4165–4172.

Estey E.H. , Thall P.F. , Cortes J.E. Comparison of idarubicin + ara-C, fludarabine + ara-C, and topotecan + ara-C-based regimens in the treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood. 2001; 98: 3575–3583.

Cutler C.S. , Lee S.J. , Greenberg P. A decision analysis of allogeneic bone marrow transplantation for myelodysplastic syndromes: delayed transplantation for low risk myelodysplasia is associated with improved outcome. Blood. 2004; 104: 579–585.

Sierra J. , Pérez W.S. , Rozman C. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002; 100: 1997–2004.

Killick S.B. , Mufti G. , Cavenagh J.D. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with “low-risk” myelodysplasia. Br J Haematol. 2003; 120: 679–684.

Raza A. , Meyer P. , Dutt D. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood. 2001; 98: 958–965.

Strupp C. , Germing U. , Aivado M. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia. 2002; 16: 1–6.

Musto P. Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leuk Res. 2004; 28: 325–332.

Musto P. , Falcone A. , Sanpaolo G. Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes. Haematologica. 2002; 87: 884–886.

Benesch M. , McDonald G.B. , Schubert M. Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study. Bone Marrow Transplant. 2003; 32: 1071–1075.

List A.F. , Schiller G.J. , Mason J. Trisenox (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): preliminary findings in a phase 2 clinical study. Poster presentation at the ASH 45th Annual Meeting. Blood. 2003; 102. Abstract 1539.

List A.F. , Kurtin S. , Glinsmann-Gibson B. Efficacy and safety of CC5013 for treatment of anemia in patients with myelodysplastic syndromes (MDS). Blood. 2003; 102. Abstract 641.

Faderl S. , Kantarjian H.M. Novel therapies for myelodysplastic syndromes. Cancer. 2004; 101: 226–241.

Lancet J.E. , Karp J.E. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood. 2003; 102: 3880–3889.

Lancet J.E. , Gojo I. , Gotlib J. Tipifarnib (Zarnestra) in previously untreated poor-risk AML and MDS: interim results of a phase 2 trial. Blood. 2003; 102. Abstract 613.